metformin and alpha-synuclein

metformin has been researched along with alpha-synuclein in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (66.67)	24.3611
2020's	3 (33.33)	2.80

Authors

Authors	Studies
Ardah, MT; Dulovic, M; El-Agnaf, OM; Harhaji-Trajkovic, L; Jovanovic, M; Kostic, V; Kravic-Stevovic, T; Markovic, I; Paunovic, V; Stefanis, L; Trajkovic, V; Xilouri, M	1
Ciociaro, A; Di Monte, DA; Hettich, MM; Kahle, PJ; Krauss, S; Pérez-Revuelta, BI; Rotermund, C	1
Jakova, E; Lee, JS	1
Bhurtel, S; Choi, DY; Jeong, GS; Katila, N; Neupane, S; Ojha, U; Shadfar, S; Srivastav, S	1
Abbas, KM; Abulseoud, OA; Ali, AN; El-Mesery, M; El-Shafey, M; Eldosoky, M; Hussein, AM	1
Korolenko, TA; Pupyshev, AB; Tikhonova, MA	1
Choudhury, SR; Karmakar, S; Kaundal, B; Sardoiwala, MN; Srivastava, AK	1
Chalorak, P; Malaiwong, N; Meemon, K; Praputpittaya, T; Saewanee, N	1
Agar, A; Aslan, M; Nemutlu-Samur, D; Ozbey, G; Parlak, H; Tanriover, G; Yildirim, S	1

Reviews

1 review(s) available for metformin and alpha-synuclein

Article	Year
[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 2016, Volume: 66, Issue:5 Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Clinical Trials as Topic; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Metformin; Molecular Chaperones; Molecular Targeted Therapy; Neuroprotective Agents; Parkinson Disease; Proteasome Endopeptidase Complex; Sirolimus; TOR Serine-Threonine Kinases; Ubiquitin	2016

Article

Year

[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy].

Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 2016, Volume: 66, Issue:5

Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Clinical Trials as Topic; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Metformin; Molecular Chaperones; Molecular Targeted Therapy; Neuroprotective Agents; Parkinson Disease; Proteasome Endopeptidase Complex; Sirolimus; TOR Serine-Threonine Kinases; Ubiquitin

2016

Other Studies

8 other study(ies) available for metformin and alpha-synuclein

Article	Year
The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiology of disease, 2014, Volume: 63 Topics: alpha-Synuclein; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cell Death; Cell Differentiation; Cells, Cultured; Cerebral Cortex; Culture Media, Conditioned; DNA Fragmentation; Embryo, Mammalian; Humans; Hypoglycemic Agents; Metformin; Neuroblastoma; Neurons; Protein Serine-Threonine Kinases; Rats; Ribonucleotides; RNA, Small Interfering; Tretinoin	2014
Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell death & disease, 2014, May-08, Volume: 5 Topics: alpha-Synuclein; AMP-Activated Protein Kinases; Animals; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Gestational Age; HeLa Cells; Hippocampus; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, Inbred C57BL; Neurons; Phosphorylation; Primary Cell Culture; Protein Kinase Inhibitors; Protein Phosphatase 2; Serine; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection	2014
Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field. Electrophoresis, 2017, Volume: 38, Issue:2 Topics: alpha-Synuclein; Caffeine; Electricity; Electrophoresis; Humans; Metformin; Models, Chemical; Nanopores; Nicotine; Parkinson Disease; Pharmaceutical Preparations	2017
Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease. Neuropharmacology, 2017, Volume: 125 Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Survival; Dopamine; Dopaminergic Neurons; Humans; Male; Membrane Glycoproteins; Metformin; Mice, Inbred C57BL; MPTP Poisoning; Neuroprotective Agents; Phosphorylation; Proof of Concept Study; Protein Phosphatase 2; Receptor, trkB; Substantia Nigra; Tyrosine 3-Monooxygenase	2017
Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy. Canadian journal of physiology and pharmacology, 2019, Volume: 97, Issue:1 Topics: alpha-Synuclein; Animals; Apoptosis; Convulsants; Epilepsy; Male; Metformin; Pentylenetetrazole; Rats; Rats, Sprague-Dawley	2019
Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-α-synuclein in Parkinson's disease model. Nanomedicine : nanotechnology, biology, and medicine, 2020, Volume: 24 Topics: alpha-Synuclein; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Humans; Indoles; Metformin; Models, Biological; Nanostructures; Parkinson Disease; Polymers; Proteasome Endopeptidase Complex; Proteolysis	2020
Neuroprotective effect of metformin on dopaminergic neurodegeneration and α-synuclein aggregation in C. elegans model of Parkinson's disease. Neuroscience research, 2021, Volume: 162 Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disease Models, Animal; Dopaminergic Neurons; Metformin; Neuroprotective Agents; Parkinson Disease	2021
Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation. Pharmacological reports : PR, 2020, Volume: 72, Issue:5 Topics: alpha-Synuclein; Animals; Dopamine; Dopaminergic Neurons; Lipid Peroxidation; Male; Metformin; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Neuroprotective Agents; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase	2020